SinoMab BioScience is set to become the tenth biotech listing in Hong Kong so far this year as it looks to raise HK$1.75 billion $223 million from an initial public offering.
The Hong Kong-headquartered firm seeks to sell 182 million shares priced between HK$7.6 and HK$9.6 according to the deal prospectus, with a roadshow underway.
Around $60 million worth of shares have been set aside for cornerstone investors, Yunnan Baiyao Group and Reach Software.
The pharmaceutical firm is the latest in a series of IPOs to launch this month, bringing the total value of Hong Kong IPO shares...
¬ Haymarket Media Limited. All rights reserved.
